Risk of prolonged commercialization and market launch of biomarker products
First written in FY2017. 2 of 5 entries say "Restated". Latest entry: FY2024.
0 other companies' latest entry also says "Mitigated".
- FY2024MitigatedAnnual report
「To minimise the risks arising from delays in new development, our group reviews the priorities of development projects and has established a system for management to conduct reviews and make decisions quickly each month. We will also promote innovation by having researchers and engineers devote a certain proportion of their working hours to new development and by budgeting the costs necessary to generate new ideas.」
In response to the risks of failure and delays in new development, the company has specified measures including reviewing project priorities, monthly management reviews, and securing development time and budgets. - FY2021ReframedAnnual report
「Our group's growth is driven primarily by innovation through new development. Since failure is inherent in highly novel development, development may be abandoned because of insurmountable obstacles, or more obstacles than anticipated may arise that must be overcome to achieve the expected results, potentially lengthening the time required to achieve those results.」
The scope of the discussion has been expanded from the previous risk of prolonged development of biomarker products to risks of failure, obstacles and prolonged development periods across new development in general. - FY2020RestatedAnnual report
「In general, the development of testing agents and other products requires a certain amount of time and expense. If the launch and sale of products using our biomarkers are delayed, this may affect our group's business performance and future business development.」
We continue to identify the risk that the launch and commercialisation of biomarker products may be prolonged. - FY2019RestatedAnnual report
「In general, the development of pharmaceuticals, including diagnostic agents, as well as testing equipment and other products, requires substantial costs and many years, and the timing of marketing authorisation is also uncertain.」
We continue to identify as a risk the substantial costs and lengthy period required to commercialise and launch biomarker products. - FY2017First statedAnnual report
「In general, the development of pharmaceuticals, including diagnostic agents, as well as testing equipment and other products, requires substantial costs and many years, and the timing of marketing authorisation is also uncertain.」
The company identifies as a risk to its biomarker business the substantial costs and lengthy development period required for product development, as well as the possibility that marketing authorisation may be delayed.